Izvorni znanstveni članak

Prognostic value of aberrant phenotypes in acute myeloid leukemia

Mirta Mikulić ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Vedran Hostić ; Zavod za hitnu medicinu grada Zagreba, Zagreb, Hrvatska
Drago Batinić ; Zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Ranka Serventi-Seiwerth ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Renata Zadro ; Zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Sanja Davidović ; Zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Klara Dubravčić ; Zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Pavle Rončević ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Damir Nemet ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Boris Labar ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska

Sažetak

Aim: Diagnosis of acute myeloid leukemia (AML) is based on cytomorphological, immunophenotypic and cytogenetic findings. The main role of immunophenotyping is lineage assignement and detection of aberrant phenotypes. The objective of this study was to analyze the incidence and the prognostic value of aberrant phenotypes in AML. Methods: Data on diagnosis and treatment of 123 patients with newly diagnosed AML, treated in the University Hospital Center Zagreb in the period from 2000-2007, was retrospectively analyzed. Results: The incidence of aberrant phenotypes was 74.8 %. The most frequent aberrant phenotype was asynchronous expression which was found in 70 % of patients, followed by co-expression of lymphoid markers in 35 % of patients and loss of lineage-specific markers in 24 % of patients. The aberrant phenotype CD33-CD13+ correlates with lower complete remission rate, while the aberrant phenotype CD117+C34+CD15+/CD14+/CD11b+ correlates with shorter overall and disease-free survival. Discussion and conclusion: In addition to its diagnostic role, immunophenotyping of AML offers information about patient prognosis through the detection of aberrant phenotypes.

Ključne riječi

aberrant immunophenotype; acute myeloid leukemia; immunophenotyping

Hrčak ID:

76670

URI

https://hrcak.srce.hr/76670

Datum izdavanja:

1.12.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.000 *